UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Blood, 2017-08, Vol.130 (6), p.732-741

2017

Volltextzugriff (PDF)

Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition

Cell cycle (Georgetown, Tex.), 2013-07, Vol.12 (13), p.2113-2119

2013

Volltextzugriff (PDF)

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

Nature medicine, 2015-03, Vol.21 (3), p.231-238

2015

Volltextzugriff (PDF)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma

Oncotarget, 2021-07, Vol.12 (15), p.1555-1563

2021

Volltextzugriff (PDF)

Preparation of Extracellular Matrices Produced by Cultured and Primary Fibroblasts

Current protocols in cell biology, 2016-06, Vol.71 (1), p.10.9.1-10.9.34

2016

Volltextzugriff (PDF)

Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma

Clinical cancer research, 2020-11, Vol.26 (22), p.5895-5902

2020

Volltextzugriff (PDF)

c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial―mesenchymal transition and invasion in prostate cancer

Carcinogenesis (New York), 2012-10, Vol.33 (10), p.1965-1975

2012

Volltextzugriff (PDF)

Stroma-Derived Three-Dimensional Matrices Are Necessary and Sufficient to Promote Desmoplastic Differentiation of Normal Fibroblasts

The American journal of pathology, 2005-08, Vol.167 (2), p.475-488

2005

Volltextzugriff (PDF)

Combination Therapy with Epigallocatechin-3-Gallate and Doxorubicin in Human Prostate Tumor Modeling Studies: Inhibition of Metastatic Tumor Growth in Severe Combined Immunodeficiency Mice

The American journal of pathology, 2010-12, Vol.177 (6), p.3169-3179

2010

Volltextzugriff (PDF)

Role of ribosomal protein RPS2 in controlling let-7a expression in human prostate cancer

Molecular cancer research, 2011-01, Vol.9 (1), p.36-50

2011

Volltextzugriff (PDF)

Preparation of Extracellular Matrices Produced by Cultured and Primary Fibroblasts

Current protocols in cell biology, 2007, Vol.33 (1), p.10.9.1-10.9.21

2007

Volltextzugriff (PDF)

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

Leukemia, 2020-04, Vol.34 (4), p.1197-1201

2020

Volltextzugriff (PDF)

Combination Therapy with Epigallocatechin-3-Gallate and Doxorubicin in Human Prostate Tumor Modeling Studies

The American journal of pathology, 2010-12, Vol.177 (6), p.3169-3179

2010

Volltextzugriff (PDF)

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

The New England journal of medicine, 2023-09, Vol.389 (11), p.1009-1022

2023

Volltextzugriff (PDF)

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Nature medicine, 2018-08, Vol.24 (8), p.1167-1177

2018

Volltextzugriff (PDF)

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

Blood, 2023-11, Vol.142 (Supplement 1), p.3289-3289

2023

Volltextzugriff (PDF)

RRMM and Post-BCMA Treated Subjects from the CC-220-MM-001 Study Show Increased Genomic Aberrations Associated with High-Risk and Significant Dysfunction in CD4+ T-Cell Compartment Compared to NDMM Subjects

Blood, 2023-11, Vol.142 (Supplement 1), p.4665-4665

2023

Volltextzugriff (PDF)

CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2/M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.2669-2669

2021

Volltextzugriff (PDF)

P-335 Iberdomide Is Immune Stimulatory and Induces Deep Anti-Myeloma Activity Across Doses in Combination With Daratumumab in Patients With TNE NDMM From the CC-220-MM-001 Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S227-S227

2024

Volltextzugriff (PDF)

ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment

Blood, 2019-11, Vol.134 (Supplement_1), p.4406-4406

2019

Volltextzugriff (PDF)

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.3318-3318

2023

Volltextzugriff (PDF)

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Blood, 2023-11, Vol.142 (Supplement 1), p.4686-4686

2023

Volltextzugriff (PDF)

Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.1613-1613

2021

Volltextzugriff (PDF)

Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro

Blood, 2018-11, Vol.132 (Supplement 1), p.1935-1935

2018

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(71)

Publikationsform

Sprache

Englisch
(76)

Erscheinungsjahr

n.n

Thema

Humans
(14)
Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Male
(8)
Female
(7)
Animals
(6)
Cell Biology
(6)
Mice
(6)
Oncology
(6)
Hematology
(5)
Multiple Myeloma
(5)
Cell Line, Tumor
(4)
Clinical Trial
(4)
Medicine, Research & Experimental
(4)
Multiple Myeloma - Drug Therapy
(4)
Neoplasm Recurrence, Local - Pathology
(4)
Research & Experimental Medicine
(4)
Adaptor Proteins, Signal Transducing - Genetics
(3)
Aged
(3)
Biological And Medical Sciences
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma

Preparation of Extracellular Matrices Produced by Cultured and Primary Fibroblasts

Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma

c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial―mesenchymal transition and invasion in prostate cancer

Stroma-Derived Three-Dimensional Matrices Are Necessary and Sufficient to Promote Desmoplastic Differentiation of Normal Fibroblasts

Combination Therapy with Epigallocatechin-3-Gallate and Doxorubicin in Human Prostate Tumor Modeling Studies: Inhibition of Metastatic Tumor Growth in Severe Combined Immunodeficiency Mice

Role of ribosomal protein RPS2 in controlling let-7a expression in human prostate cancer

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE‐EXPANSION PHASE OF THE CC‐92480‐MM‐001 TRIAL

Preparation of Extracellular Matrices Produced by Cultured and Primary Fibroblasts

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

Combination Therapy with Epigallocatechin-3-Gallate and Doxorubicin in Human Prostate Tumor Modeling Studies

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

RRMM and Post-BCMA Treated Subjects from the CC-220-MM-001 Study Show Increased Genomic Aberrations Associated with High-Risk and Significant Dysfunction in CD4+ T-Cell Compartment Compared to NDMM Subjects

CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2/M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

P-335 Iberdomide Is Immune Stimulatory and Induces Deep Anti-Myeloma Activity Across Doses in Combination With Daratumumab in Patients With TNE NDMM From the CC-220-MM-001 Study

ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma

Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro

Suchergebnisse filtern